A Centers for Disease Control panel said that despite the rare risk of blood clots, the vaccine suspension should be lifted.
A U.S. health panel said on Friday it was time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots.
The recommendation from the Centers for Disease Control and Prevention (CDC) paves the way for the resumption of J&J shooting at guns in the United States after regulators suspended its use earlier this month to review reports of rare but serious blood clots associated with low blood. platelets.
CDC advisers said Friday that the vaccine’s benefits outweighed this serious but small risk – especially against a virus that still infects tens of thousands of Americans every day. The government will quickly assess this recommendation to decide on the next steps.
Senior health officials have said they hope for an early return to use of the vaccine.
“The benefits clearly outweigh the risk from a population and individual perspective,” said Dr. Beth Bell, advisory board member and clinical professor in the Department of Global Health at the University of Washington in Seattle.
“It’s a new risk. This is admittedly an extremely low risk and lower than many other risks we choose to take every day, ”she added.
“The Committee’s recommendation is an essential step towards the continued safe continuation of urgently needed vaccinations for millions of people in the United States,” J&J Scientific Director Paul Stoffels said in a statement.
He added that the company will continue to work with the CDC, the FDA and health authorities in Europe “to ensure that this very rare event can be identified early and treated effectively.”
Of nearly eight million people vaccinated before the United States suspended firing on J&J earlier this month, health officials discovered 15 cases of a very unusual type of blood clot, including three fatalities. All were women, most of them under the age of 50.
The CDC and the Food and Drug Administration (FDA) initially spotted six people who developed such clots one to three weeks after their J&J vaccination, including one death. The investigation then widened when the government received what Walensky called “a handful” of additional clot reports, including a death which state officials say is under investigation. in Oregon.
Reports of needles in a haystack have sounded the alarm because European regulators had previously discovered similar rare clots in recipients of another COVID-19 vaccine, from Oxford-AstraZeneca. The AstraZeneca and J&J blueprints, although not identical, are made with the same technology.
European scientists have found clues that an abnormal, platelet-damaging immune response to AstraZeneca’s vaccine could be to blame – and if so, doctors should avoid the most common treatment for clots, a blood thinner called heparin.
This has added to the urgency for US officials to suspend J&J vaccinations so they can tell doctors how to diagnose and treat these rare clots. Several initial patients were treated with heparin before anyone realized that it could harm rather than help patients.